Two-dimensional structures in the quintic Ginzburg-Landau equation

By using ZEUS cluster at Embry-Riddle Aeronautical University we perform extensive numerical simulations based on a two-dimensional Fourier spectral method Fourier spatial discretization and an explicit scheme for time differencing) to find the range of existence of the spatiotemporal solitons of the two-dimensional complex Ginzburg-Landau equation with cubic and quintic nonlinearities. We start from the parameters used by Akhmediev {\it et. al.} and slowly vary them one by one to determine the regimes where solitons exist as stable/unstable structures. We present eight classes of dissipative solitons from which six are known (stationary, pulsating, vortex spinning, filament, exploding, creeping) and two are novel (creeping-vortex propellers and spinning "bean-shaped" solitons). By running lengthy simulations for the different parameters of the equation, we find ranges of existence of stable structures (stationary, pulsating, circular vortex spinning, organized exploding), and unstable structures (elliptic vortex spinning that leads to filament, disorganized exploding, creeping). Moreover, by varying even the two initial conditions together with vorticity, we find a richer behavior in the form of creeping-vortex propellers, and spinning "bean-shaped" solitons. Each class differentiates from the other by distinctive features of their energy evolution, shape of initial conditions, as well as domain of existence of parameters.Comment: 19 pages, 19 figures, 8 tables, updated text and reference

2D Novel Structures Along an Opitcal Fiber

By using spectral methods, we present seven classes of stable and unstable structures that occur in a dissipative media. By varying parameters and initial conditions we find ranges of existence of stable structures (spinning elliptic, pulsating, stationary, organized exploding), and unstable structures (filament, disorganized exploding, creeping). By varying initial conditions, vorticity, and parameters of the equation, we find a reacher behavior of solutions in the form of creeping-vortex (propellers), spinning rings and spinning “bean-shape” solitons. Each class differentiates from the other by distinctive features of their shape and energy evolution, as well as domain of existence

2D Novel Structures Along an Opitcal Fiber

By using spectral methods, we present seven classes of stable and unstable structures that occur in a dissipative media. By varying parameters and initial conditions we find ranges of existence of stable structures (spinning elliptic, pulsating, stationary, organized exploding), and unstable structures (filament, disorganized exploding, creeping). By varying initial conditions, vorticity, and parameters of the equation, we find a reacher behavior of solutions in the form of creeping-vortex (propellers), spinning rings and spinning “bean-shape” solitons. Each class differentiates from the other by distinctive features of their shape and energy evolution, as well as domain of existence

Additional file 1 of Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Additional file 1: Supplementary Methods, Results, Tables and Figures

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients : a randomised controlled trial

Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventilated subjects. Methods: EVADE (NCT02696902) was a phase 2, randomised, parallel-group, double-blind, placebo-controlled study in Europe, Turkey, Israel, and the USA. Subjects ≥ 18 years old, mechanically ventilated, tracheally colonised with PA, and without new-onset pneumonia, were randomised (1:1:1) to MEDI3902 500, 1500 mg (single intravenous dose), or placebo. The primary efficacy endpoint was the incidence of nosocomial PA pneumonia through 21 days post-dose in MEDI3902 1500 mg versus placebo, determined by an independent adjudication committee. Results: Even if the initial sample size was not reached because of low recruitment, 188 subjects were randomised (MEDI3902 500/1500 mg: n = 16/87; placebo: n = 85) between 13 April 2016 and 17 October 2019. Out of these, 184 were dosed (MEDI3902 500/1500 mg: n = 16/85; placebo: n = 83), comprising the modified intent-to-treat set. Enrolment in the 500 mg arm was discontinued due to pharmacokinetic data demonstrating low MEDI3902 serum concentrations. Subsequently, enrolled subjects were randomised (1:1) to MEDI3902 1500 mg or placebo. PA pneumonia was confirmed in 22.4% (n = 19/85) of MEDI3902 1500 mg recipients and in 18.1% (n = 15/83) of placebo recipients (relative risk reduction [RRR]: − 23.7%; 80% confidence interval [CI] − 83.8%, 16.8%; p = 0.49). At 21 days post-1500 mg dose, the mean (standard deviation) serum MEDI3902 concentration was 9.46 (7.91) μg/mL, with 80.6% (n = 58/72) subjects achieving concentration